RxDoctor Payments Data

Scott Jenkins, MD

Internal Medicine · Newport Beach, CANPI 1528009743

Payments from drug & device makers

$840in general payments, 2019–2025

Across 46 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$246
  • Pfizer$244
  • Amarin Pharma, Inc.$90
  • Amgen$67
  • Sanofi Pasteur Inc.$36
  • Merck$28
  • plus $128 from 7 others

What the payments were for

  • Food & beverage$83599%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$840 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$334,949
Medicare patients
443
Services billed
7,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$242,981
TrulicityDulaglutide89$106,254
ProliaDenosumab45$77,180
OzempicSemaglutide71$71,710
FarxigaDapagliflozin Propanediol59$67,392
JanuviaSitagliptin Phosphate54$57,142
XareltoRivaroxaban43$54,679
JardianceEmpagliflozin22$35,404
MyrbetriqMirabegron30$32,874
Repatha SureclickEvolocumab34$30,281
EdarbiAzilsartan Medoxomil25$12,226
Lagevrio (Eua)Molnupiravir13$9,904
SynthroidLevothyroxine Sodium121$8,995
Breo ElliptaFluticasone/Vilanterol18$8,685
Rosuvastatin Calcium481$7,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$244$245,717276 claims
Lilly USA, LLCTrulicity$19$106,25489 claims
AmgenProlia$67$77,18045 claims
Novo NordiskOzempic$19$71,71071 claims
AstraZenecaFarxiga$15$67,39259 claims
MerckJanuvia, Lagevrio (Eua)$28$67,04667 claims
Johnson & JohnsonXarelto$246$54,67943 claims
Astellas Pharma US IncMyrbetriq$23$32,87430 claims
Arbor Pharmaceuticals, Inc.Edarbi$24$12,22625 claims
AbbVieSynthroid$16$8,995121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →